Skip to main content

Table 1 Classification and clinical course of the study population, i.e., 63 patients with rheumatic/vasculitic or connective tissue disease admitted to hospital and diagnosed to have pneumonia/pneumonitis

From: Occurrence of HSV-1-induced pneumonitis in patients under standard immunosuppressive therapy for rheumatic, vasculitic, and connective tissue disease

 

Total admissions to hospital

Admissions for PNA (% of admissions)

FOB with BAL in PNA (% of PNA)

BAL-PCR for HSV-1 and CMV (% of FOB)

Positive HSV-1 BAL-PCR (% of PNA)

Requirement of intubation in PNA (% of PNA)

Mean and (median) age of patients with PNA in ys

Mean immuno-suppression severity score of patients with PNA*

Lethal outcome in PNA

Wegener's Granulomatosis

74

13 (18%)

4

4

2 (cases 3, 5)

2

66 (68)

3.3

2

Rheumatoid arthritis

515

34 (7%)

12

6

2 (cases 1,4)

5

71 (74)

1.5

3

Polyangiits

22

4 (18%)

3

1

1 (case 2)

0

63 (64)

3.5

0

Systemic lupus erythematosus (SLE)

155

12 (8%)

4

3

1 (case 6)

1

53 (58)

1.6

1

total

766

63 (8%)

23 (37%)

14 (61%)

6 (10%)

8 (12%)

66 (66)

2.0

6 (10%)

  1. Absolute numbers or percentages are given, (*) based on 56 of the 63 cases where information on immunosuppressive regimens was reliably available. In order to estimate the degree of immunosuppressive strength in the patient population, an arbitrary score ranging form 0–4 was applied (see methods). Abbreviations: BAL = bronchoalveolar lavage, FOB = fiberoptic bronchoscopy, PNA = pneumonia/pneumonitis, ys = years.